Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Levomekol is a topical combination ointment manufactured by Viola Pharmaceutica Fabrika. It contains two active ingredients: chloramphenicol (levomycetin), a broad-spectrum antibiotic, and methyluracil, a tissue regeneration stimulant. Chloramphenicol exerts its antimicrobial effect by binding to the bacterial 50S ribosomal subunit, thereby inhibiting protein synthesis in a wide range of gram-positive and gram-negative bacteria, including staphylococci and *E. coli*. Methyluracil promotes wound healing by stimulating cellular regeneration and nucleic acid metabolism. The ointment is primarily indicated for the treatment of purulent wounds in the first phase of the wound process, as well as boils, trophic ulcers, and infected burns. It exhibits combined antimicrobial, anti-inflammatory, and reparative actions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Levomekol.